Dose-related effects of phenobarbitone on human sleep-waking patterns.
1 Twenty-four healthy male subjects had two consecutive drug nights at 2-week intervals using placebo and 80, 140 and 240 mg doses of phenobarbitone in a double-blind cross-over design. 2 Phenobarbitone produced significant dose-related decreases in sleep latency and number of awakenings, along with increased total sleep time. 3 Both subjective and objective measures of sleep indicated the presence of cumulative (first v second night) effects of phenobarbitone, especially decreases in the number of awakenings and in delta waveform activity. 4 Measures of REM sleep were highly sensitive to phenobarbitone. The high dose decreased REM density to 30% of baseline on the first night and to 18% on the second night. 5 EEG alpha activity was decreased, beta activity was increased and sigma spindle activity was unaffected by phenobarbitone during sleep. 6 Subjects experienced some impairment of cognitive performance along with residual sedation the following morning.
D000328:Adult; D003071:Cognition / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D004585:Electrooculography; D004644:Emotions / Q000187:drug effects; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010634:Phenobarbital / Q000009:adverse effects / Q000494:pharmacology*; D012890:Sleep / Q000187:drug effects* / Q000502:physiology; D011795:Surveys and Questionnaires; D014851:Wakefulness / Q000187:drug effects*
D010634:Phenobarbital